Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Carisma Therapeutics, Inc. - Common Stock Market Cap
Based on ratings from 5 stock analysts, the Carisma Therapeutics, Inc. - Common Stock stock price is expected to increase by 1023.19% in 12 months. This is calculated by using the average 12-month stock price forecast for Carisma Therapeutics, Inc. - Common Stock. The lowest target is $4 and the highest is $12. Please note analyst price targets are not guaranteed and could be missed completely.
About 5 Wall Street analysts have assignedCARM 4 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Carisma Therapeutics, Inc. - Common Stock to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CARM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CARM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Justin Zelin BTIG | Neutral | Downgrade | Dec 10, 2024 | |
| Jason Kolbert D. Boral Capital | Buy | $12 | Maintains | Dec 9, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $5 | Maintains | Nov 25, 2024 |
| Jason Kolbert D. Boral Capital | Buy | $24 | Maintains | Nov 18, 2024 |
| Jason Kolbert D. Boral Capital | Buy | $24 | Maintains | Nov 11, 2024 |
| Jason Kolbert EF Hutton | Buy | $24 | Maintains | Nov 7, 2024 |
| Jason Kolbert EF Hutton | Buy | $24 | Initiates | Oct 30, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $8 | Reiterates | Jun 28, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $8 | Reiterates | Jun 26, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $8 | Reiterates | May 17, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $8 | Maintains | May 10, 2024 |
| Justin Zelin BTIG | Buy | $6 | Initiates | Apr 11, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $9 | Maintains | Apr 2, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $11 | Reiterates | Nov 29, 2023 |
| Naureen Quibria Capital One | Overweight | $10 | Initiates | Oct 3, 2023 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $11 | Reiterates | Sep 6, 2023 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $11 | Maintains | Aug 11, 2023 |
| Liisa Bayko Evercore ISI Group | Outperform | $12 | Initiates | Jul 6, 2023 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $10 | Reiterates | Jun 29, 2023 |
Baird | Outperform | Reiterates | Jun 28, 2023 |
When did it IPO
2014
Staff Count
107
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Steven Kelly
Market Cap
$28.9M
In 2023, CARM generated $14.9M in revenue, which was a increase of 51.71% from the previous year. This can be seen as a signal that CARM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Carisma Therapeutics is refocusing on its in vivo macrophage engineering platform for fibrosis, oncology, and autoimmune disease therapies, discontinuing CT-0525, and cutting its workforce by 34%.
Why It Matters - Carisma's shift to focus on in vivo macrophage engineering and workforce reduction signals a strategic pivot, potentially impacting future growth, costs, and investor confidence in its remaining pipeline.
Wed, 27 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Carisma Therapeutics Inc. (Nasdaq: CARM) CEO Steven Kelly will participate in a fireside chat at the Evercore ISI HealthCONx Conference on December 5 at 9:35 am ET. An audio webcast will be available.
Why It Matters - Carisma Therapeutics' CEO's upcoming participation in a major health conference could signal key insights into the company's strategy and pipeline, influencing investor sentiment and stock performance.
Sun, 17 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Carisma Therapeutics presented promising preclinical data on engineered macrophages for liver fibrosis treatment, highlighting their potential as an off-the-shelf therapy for fibrotic liver diseases.
Why It Matters - Promising preclinical data on Carisma's engineered macrophages for liver fibrosis may enhance the company's valuation and attract investment, signaling potential breakthroughs in immunotherapy.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Carisma Therapeutics (Nasdaq: CARM) will present new preclinical data in November and expects Phase 1 results of CT-0525 and a liver fibrosis candidate nomination by Q1 2025. They have $26.9M cash to fund operations into Q3 2025.
Why It Matters - Upcoming clinical trial results and preclinical data presentations could impact stock performance. The company's cash reserves suggest operational stability but require positive study outcomes for future growth.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Carisma Therapeutics announced positive pre-clinical data on its CAR-M therapy targeting hepatocellular carcinoma, developed with Moderna, indicating effective in vivo treatment potential.
Why It Matters - Positive pre-clinical data for Carisma's CAR-M therapy targeting HCC suggests potential market growth and competitive advantage, impacting stock performance for CARM and MRNA.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Carisma Therapeutics will present pre-clinical data on its anti-GPC3 CAR-M therapy for hepatocellular carcinoma at the SITC Annual Meeting on November 8, 2024, showcasing strong anti-tumor activity.
Why It Matters - The announcement of robust anti-tumor activity in Carisma's CAR-M therapy for HCC, developed with Moderna, could boost investor confidence and stock performance due to potential market impact.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
